The FDA has started a review of Hansa Biopharma's imlifidase for patients who need a kidney transplant, but for whom finding ...

Shares of Hansa Biopharma rose nearly 7% to 32.98 kronor, after the Swedish company announced that the Food and Drug ...

Two of the biggest dark web markets have been taken down by law enforcement agencies across the world, the Department of Justice (DoJ) announced today. They included AlphaBay, the biggest ever dark ...

Hansa Biopharma AB ( (SE:HNSA)) has provided an update. Hansa Biopharma announced that its Phase 3 trial for the treatment of anti-glomerular basement membrane (anti-GBM) disease with imlifidase did ...

CEO Soren Tulstrup highlighted full-year 2024 revenue of SEK 171.3 million, marking a 28% year-over-year increase, with IDEFIRIX product sales contributing SEK 140.1 million after provisions.

For anyone who has watched the last few years of cat-and-mouse games on the dark web's black markets, the pattern is familiar: A contraband bazaar like the Silk Road attracts thousands of drug dealers ...

If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. Lund, Sweden, 4 March 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), ...